Aviptadil for COVID-19: Trial Results

The early trial

Aviptadil is synthetic vasoactive intestinal peptide, a molecule studied for several biological effects in the lungs. An early randomized trial enrolled 196 people with COVID-19 respiratory failure across ten US hospitals. It compared intravenous aviptadil with placebo and assessed whether patients were alive and free of respiratory failure at day sixty ^[1].

That primary endpoint did not reach statistical significance. The investigators nevertheless reported a favorable secondary survival result and several subgroup signals, including findings among patients receiving particular forms of respiratory support. These were observations within a trial whose principal comparison had failed, and should be described with that limitation ^[1].

The larger test

TESICO studied hospitalized adults with COVID-19-associated acute hypoxemic respiratory failure. For the aviptadil comparison, 471 participants were randomized and 461 who received at least part of an infusion entered the modified intention-to-treat analysis. Most were in intensive care when enrolled ^[2].

The primary outcome ranked patients at day ninety according to survival, hospitalization, oxygen needs and time recovered at home. Aviptadil did not significantly improve that outcome: the odds ratio was 1.11, with a 95% confidence interval of 0.80 to 1.55 and p = 0.54. An independent monitoring board recommended stopping the aviptadil trial for futility ^[2].

Mortality and adverse outcomes

By day ninety, 86 participants assigned aviptadil and 83 assigned placebo had died. The reported cumulative mortality percentages were 38 percent and 36 percent, respectively; the mortality comparison was not statistically significant. These findings did not confirm a survival benefit suggested by the earlier trial ^[2].

The main early safety composite occurred in 63 percent of the aviptadil group and 56 percent of the placebo group. That comparison also did not reach statistical significance. It should not be described as proof of increased harm, but neither does it justify a sweeping assurance of safety in every setting ^[2].

What remains uncertain

TESICO also included a remdesivir comparison with a much smaller sample, which the authors considered insufficient for definitive conclusions. That limitation belongs to the remdesivir comparison and should not be used to dismiss the separate aviptadil findings. The trial design allowed participants to enter one or both comparisons ^[2].

The evidence reviewed here concerns severe acute COVID-19 in hospitalized patients. It does not establish benefit for long COVID, chronic environmental-illness claims or routine respiratory wellness. The VIP monograph separates these trial results from the molecule’s regulatory position; permission to compound and proof of clinical benefit remain different questions.

Elsewhere in this index